Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Classical hematology 1

Conditions

Multiple Myeloma 5Neoplasms 3Glioma 2Unspecified Childhood Solid Tumor, Protocol Specific 1Rhabdoid Tumor 1Ovarian Neoplasms 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Medulloblastoma 1Glioblastoma 1Fallopian Tube Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1Anemia 1

Interventions

peginesatide 2hematide 2Lenalidomide 2venetoclax 1trametinib 1ruxolitinib 1reolysin 1regorafenib 1ponatinib 1pertuzumab 1pembrolizumab 1palbociclib 1olaparib 1neratinib 1lorlatinib 1lenvatinib 1iron isomaltoside 1000 1idelalisib 1enzalutamide 1entrectinib 1enasidenib 1durvalumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1dehydroftorafur 1darolutamide 1dacomitinib 1dabrafenib 1copanlisib 1cobimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Anemia × reolysin × Clear all
NCT02101944 2024-05-17

Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled
Classical hematologyPlasma cell

Anemia, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡